Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
1 Department of Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University, Shanghai, China. [email protected].
2 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
3 Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
4 Department of Respiratory Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Hospital, Hefei, China.
5 Department of Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
6 Department of Oncology, Shengjing Hospital of China Medical University, Huaxiang Branch Hospital, Shenyang, China.
7 Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
8 Thoracic Oncology, Sichuan Cancer Hospital and Institute, Chengdu, China.
9 Department of Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.
10 Department of Thoracic Oncology, Hunan Cancer Hospital, Changsha, China.
11 Department of Thoracic Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China.
12 Pharmacology Base, The First Hospital of Jilin University, Changchun, China.
13 Department of Thoracic Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Zhejiang University Cancer Centre, Hangzhou, China.
14 Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
15 Department of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
16 Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China.
17 Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
18 Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
19 Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
20 Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
21 Department of Oncology, Yantai Yuhuangding Hospital, Yantai, China.
22 Medical Oncology, Jiangsu Province Hospital, Nanjing, China.
23 Department of Respiratory Disease, Thoracic Disease Centre, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
24 Department of Oncology, Liuzhou General Hospital, Liuzhou, China.
25 Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
26 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
27 Department of Respiratory Medicine, The Second Hospital of Anhui Medical University, Hefei, China.
28 Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
29 The Second Department of Pulmonary Medicine, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.